ロード中...
Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study
BACKGROUND: Eculizumab, a terminal complement inhibitor, is approved for atypical haemolytic uraemic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). METHODS: In five parent studies, eculizumab effectively prevented TMA and improved renal and haematologic outcomes in...
保存先:
| 出版年: | Clin Kidney J |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6452204/ https://ncbi.nlm.nih.gov/pubmed/30976396 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy035 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|